JOURNAL OF THE NEUROLOGICAL SCIENCES, cilt.391, ss.72-76, 2018 (SCI-Expanded)
Background: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large global observational registry, affords a unique opportunity to investigate predictors of 'post-DMT' relapses and confirmed disability progression (CDP) in a diverse group of patients exposed to different DMTs.